1Goldstein JL, Brown MS (2009) The LDL Receptor. Arterioscler Thromb Vasc Biol 29: 431-438.

2Leander K, Mälarstig A, van't Hooft FM, et al. (2016) Circulating PCSK9 Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors. Circulation 133: 1230-1239

3Dixon DL, Trankle C, Buckley L, et al. (2016) A review of PCSK9 inhibition and its effects beyond LDL receptors. J Clin Lipidol 10: 1073-1080.

4Chaudhary R, Garg J, Shah N, Sumner A (2017) PCSK9 inhibitors: A new era of lipid lowering therapy. World J Cardiol 9: 76-91.

5Sabatine MS, Giugliano RP, Keech AC, et al. (2017) FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Eng J Med 376: 1713-1722.

6Franchini M, Montagnana M (2011) Low-density lipoprotein receptor-related protein 1: new functions for an old molecule. Clin Chem Lab Med 49: 967-990

7Wang M, Li Y-F, Guo Y-G, Chen M-M, Jiang Z-L, Song J-Y (2016) Positive correlation between plasma PCSK9 and tissue factors levels in patients with angiographically diagnosed coronary artery disease and diabetes mellitus. J Geriatric Card 13: 312-315.

8Farrehi PM, Ozaki CK, Carmeliet P, Fay WP (1998) Regulation of Arterial Thrombolysis by Plasminogen Activator Inhibitor-1 in Mice. Circulation 97:1002-1208.

9Ren M, Li R, Chen N, et al. (2017) Platelet‐Derived Factor V Is a Critical Mediator of Arterial Thrombosis. J Am Heart Assoc 6: pii: e006345.

10asuja R, Passam FH, Kennedy DR, et al. (2012) Protein disulfide isomerase inhibitors constitute a new class of antithrombotic agents. J Clin Invest 122: 2104-2113.

11Dubois C, Panicot-Dubois L, Gainor JF, Furie BC, Furie B (2007) Thrombin-initiated platelet activation in vivo is vWF independent during thrombus formation in a laser injury model. J Clin Invest 117: 953-960.

12Luo M, Ji Y, Luo Y, Li R, Fay WP, Wu J (2017) Plasminogen Activator Inhibitor-1 Regulates the Vascular Expression of Vitronectin. J Thromb Haemost 15: 2451-2460.

13Nagy B, Jin J, Ashby B, Reilly MP, Kunapuli SP (2011) Contribution of the P2Y12 receptor-mediated pathway to platelet hyperreactivity in hypercholesterolemia. J Thromb Haemost 9: 810-819.

14Dorsam RT, Kunapuli SP (2004) Central role of the P2Y(12) receptor in platelet activation. J Clin Invest 113: 340-345.

15Van Kolen K, Gilany K, Moens L, Esmans EL, Slegers H (2006) P2Y12 receptor signalling towards PKB proceeds through IGF-I receptor cross-talk and requires activation of Src, Pyk2 and Rap1. Cellular Signalling 18: 1169-1181.

16Zaid A, Roubtsova A, Essalmani R, et al. (2008) Prat A. Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology 48: 646-654.

17van Willigen G, Gorter G, Akkerman JW (1994) LDLs increase the exposure of fibrinogen binding sites on platelets and secretion of dense granules. Arterioscler Thromb 14: 41-46.

18Eitzman DT, Westrick RJ, Xu Z, Tyson J, Ginsburg D (2000) Hyperlipidemia Promotes Thrombosis After Injury to Atherosclerotic Vessels in Apolipoprotein E–Deficient Mice. Arterioscler Thromb Vasc Biol 20: 1831-1834.

19Lakoski SG, Lagace TA, Cohen JC, Horton JD, Hobbs HH (2009) Genetic and Metabolic Determinants of Plasma PCSK9 Levels. J Clin Endocrinol Metab 94: 2537-2543.

20Cunningham Margaret R, Nisar Shaista P, Mundell Stuart J (2013) Molecular mechanisms of platelet P2Y12 receptor regulation. Biochem Soc Trans 41: 225-230.

21Nisar SP, Cunningham M, Saxena K, Pope RJ, Kelly E, Mundell SJ (2012) Arrestin Scaffolds NHERF1 to the P2Y12 Receptor to Regulate Receptor Internalization. J Biol Chem 287: 24505-24515.

22Hardy AR, Jones ML, Mundell SJ, Poole AW (2004) Reciprocal cross-talk between P2Y1 and P2Y12 receptors at the level of calcium signaling in human platelets. Blood 104: 1745-1752.

23Wang H, Wang Q, Wang J, et al. (2017) Proprotein convertase subtilisin/kexin type 9 (PCSK9) Deficiency is Protective Against Venous Thrombosis in Mice. Scientific Reports 7: 14360.

24Navarese EP, Kolodziejczak M, Winter M-P, et al. (2017) Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study. Int J Cardiol 227: 644-649.

25Camera M, Rossetti L, Barbieri SS, et al. (2018) PCSK9 as a Positive Modulator of Platelet Activation. J Am Coll Cardiol 71: 952-954.

26Navarese EP, Kolodziejczak M, Winter MP, et al. (2017) Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study. Int J Cardiol 227:644-649.